Invention Grant
US08524230B2 Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
失效
使用IL-23和IL-17拮抗剂治疗自身免疫性眼炎
- Patent Title: Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
- Patent Title (中): 使用IL-23和IL-17拮抗剂治疗自身免疫性眼炎
-
Application No.: US12643152Application Date: 2009-12-21
-
Publication No.: US08524230B2Publication Date: 2013-09-03
- Inventor: Daniel J. Cua , Robert A. Kastelein , Van T. Tsai , Rachel Caspi , Phyllis Silver
- Applicant: Daniel J. Cua , Robert A. Kastelein , Van T. Tsai , Rachel Caspi , Phyllis Silver
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Main IPC: C07K16/244
- IPC: C07K16/244 ; A61P29/00 ; C07K2316/96 ; A61K39/395
Abstract:
Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
Public/Granted literature
- US20100111950A1 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE Public/Granted day:2010-05-06
Information query
